2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108672
    NF157 104869-26-3
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).
    NF157
  • HY-141692
    IL-17 modulator 4 2446803-65-0 98.19%
    IL-17 modulator 4 is a proagent of IL-17 modulator 1 (HY-141535). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome.
    IL-17 modulator 4
  • HY-P99140
    Anti-Mouse IL-1R Antibody (JAMA-147)
    Anti-Mouse IL-1R Antibody (JAMA-147) is an anti-mouse IL-1R IgG2b antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IL-1R Antibody (JAMA-147) diminishes Spp1hi-TAM-mediated T cell suppression. Anti-Mouse IL-1R Antibody (JAMA-147) can be used for the researches of inflammation, metabolic disease and infection, such as diabetes.
    Anti-Mouse IL-1R Antibody (JAMA-147)
  • HY-P99141
    Anti-Mouse LAG-3 Antibody (C9B7W) 99%
    Anti-Mouse LAG-3 Antibody (C9B7W) is an anti-mouse LAG-3 IgG1 monoclonal antibody. Anti-Mouse LAG-3 Antibody (C9B7W) can enhance CD4+ T cell function and exert anti-tumor effects without blocking the interaction between LAG-3 and MHCII. Anti-Mouse LAG-3 Antibody (C9B7W) can be used for research on cancer such as head and neck squamous cell carcinoma (HNSCC).
    Anti-Mouse LAG-3 Antibody (C9B7W)
  • HY-P99219
    Sifalimumab 1006877-41-3 99.46%
    Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
    Sifalimumab
  • HY-P99445
    Asunercept 1450882-18-4 98.13%
    Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD).
    Asunercept
  • HY-P99496
    Cendakimab 2151032-62-9 ≥99.0%
    Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
    Cendakimab
  • HY-P99520
    Vilobelimab 2250440-41-4 ≥99.0%
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.
    Vilobelimab
  • HY-10499
    PH-064 892546-37-1 99.88%
    PH-064 (BIM-46187) is an orally active inhibitor of the heterotrimeric G-protein complex. PH-064 inhibits SERT activity and attenuates shear stress-induced Akt phosphorylation. PH-064 has potent anti-hyperalgesia activity. PH-064 inhibits G protein-coupled receptor-dependent tumorigenesis. PH-064 can be used in the study of pain (e.g., inflammatory pain, neuropathic pain), GPCR-dependent tumors, and inflammatory lung injury.
    PH-064
  • HY-14144
    Aclidinium Bromide 320345-99-1 98.96%
    Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research.
    Aclidinium Bromide
  • HY-B0559
    Nabumetone 42924-53-8 99.94%
    Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective COX-2 inhibitor, and is the proagent of the active metaboliteα-Demethylnaproxen (HY-W086896). Nabumetone can inhibit cancer cells proliferation and relieve gastric ulcers.
    Nabumetone
  • HY-B1276
    Metaproterenol hemisulfate 5874-97-5 99.44%
    Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist with an IC50 of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity.
    Metaproterenol hemisulfate
  • HY-B2145
    Ilaprazole sodium 172152-50-0 99.65%
    Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.
    Ilaprazole sodium
  • HY-N0362
    Columbianadin 5058-13-9 99.92%
    Columbianadin, a natural coumarin from Heracleum hemsleyanum, is known to have various biological activities including anti-inflammatory and anti-cancer effects.
    Columbianadin
  • HY-N0513
    Loganic acid 22255-40-9 99.05%
    Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active.
    Loganic acid
  • HY-N0671
    Rhapontin 155-58-8 99.73%
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis.
    Rhapontin
  • HY-N0885
    Telocinobufagin 472-26-4 99.93%
    Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na+/K+-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models.
    Telocinobufagin
  • HY-N1388
    Tussilagone 104012-37-5 99.52%
    Tussilagone, a major active component in Tussilago farfara, has anti-inflammatory effect. Tussilagone ameliorates inflammatory responses in dextran sulphate sodium-induced murine colitis. Tussilagone inhibits the inflammatory response and improves survival in cecal ligation and puncture (CLP)-induced septic mice.
    Tussilagone
  • HY-N1440
    Koumine 1358-76-5 99.97%
    Koumine is an alkaloid separated from Gelsemium elegans, shows potent anti-tumor activity. Koumine up-regulates the Bax/Bcl-2 ratio and caspase-3 expression in human breast cancer cells. Koumine has anxiolytic, antistress, antipsoriatic, and analgesic activities, protects against the development of arthritis in Rheumatoid arthritis (RA) animal models.
    Koumine
  • HY-N2071
    Cedrol 77-53-2 99.76%
    Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
    Cedrol
Cat. No. Product Name / Synonyms Application Reactivity